Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Denali Therapeutics (DNLI) stocks in Canada

Learn how to easily invest in Denali Therapeutics stocks.

Denali Therapeutics is a biotechnology business based in the US. Denali Therapeutics stocks (DNLI.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $74.1 – an increase of 1.25% over the previous week. Denali Therapeutics employs 360 staff and has a trailing 12-month revenue of around $353 million.

How to buy shares in Denali Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – DNLI – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Denali Therapeutics stock price (NASDAQ:DNLI)

Use our graph to track the performance of DNLI stocks over time.

Denali Therapeutics shares at a glance

Information last updated 2022-01-24.
Latest market close$33.25
52-week range$30.25 - $79.70
50-day moving average $44.09
200-day moving average $54.04
Wall St. target price$84.17
PE ratio 137.1187
Dividend yield N/A (0%)
Earnings per share (TTM) $0.24

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Denali Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Denali Therapeutics price performance over time

Historical closes compared with the close of $33.25 from 2022-01-26

1 week (2022-01-19) 0.24%
1 month (2021-12-27) -25.93%
3 months (2021-10-28) -32.03%
6 months (2021-07-28) -35.46%
1 year (2021-01-28) -53.08%
2 years (2020-01-28) 33.86%
3 years (2019-01-28) 55.59%
5 years (2017-01-24) N/A

Is Denali Therapeutics under- or over-valued?

Valuing Denali Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Denali Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Denali Therapeutics's P/E ratio

Denali Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 137x. In other words, Denali Therapeutics shares trade at around 137x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Denali Therapeutics's EBITDA

Denali Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $34.1 million.

The EBITDA is a measure of a Denali Therapeutics's overall financial performance and is widely used to measure a its profitability.

Denali Therapeutics financials

Revenue TTM $353 million
Operating margin TTM 7.21%
Gross profit TTM $123 million
Return on assets TTM 1.26%
Return on equity TTM 3.12%
Profit margin 8.38%
Book value $8.30
Market capitalisation $4 billion

TTM: trailing 12 months

Denali Therapeutics share dividends

We're not expecting Denali Therapeutics to pay a dividend over the next 12 months.

Denali Therapeutics share price volatility

Over the last 12 months, Denali Therapeutics's shares have ranged in value from as little as $30.25 up to $79.7. A popular way to gauge a stock's volatility is its "beta".

DNLI.US volatility(beta: 1.74)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Denali Therapeutics's is 1.7415. This would suggest that Denali Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Denali Therapeutics overview

Denali Therapeutics Inc. , a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc.

Stocks similar to Denali Therapeutics

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site